Top Story

Cetuximab plus radiation, cisplatin yielded little benefit in advanced head and neck cancers

September 12, 2014

The addition of cetuximab to cisplatin-based radiation therapy conferred no significant benefit with regard to PFS, OS, locoregional failure or distant metastasis in patients with stage III or stage IV head and neck carcinoma, according to results of a randomized phase 3 trial.

Rita S. Axelrod, MD, co-director of the Thoracic Oncology Program at Jefferson University Hospitals, and colleagues hypothesized that the addition of the epidermal growth factor receptor (EGFR) antagonist cetuximab (Erbitux, Eli Lilly) to accelerated radiation plus cisplatin would extend PFS in that patient population.

figure Meeting News Coverage

Toxins at Ground Zero linked with cancer among thousands of first responders

September 11, 2014
The tragedy of Sept. 11, 2001 still haunts Americans in countless ways, with many survivors continuing to struggle with the enduring grief and trauma left in its wake…
figure In the Journals

One in four patients with head, neck cancers do not receive guideline-directed adjuvant therapy

September 2, 2014
About 25% of patients with surgically resected head and neck cancers that exhibit adverse pathologic features do not receive guideline-directed adjuvant therapy with…
figure Cover StoryPublication Exclusive

Cancer treatment during pregnancy ‘a constant balancing act’

HemOnc Today, September 10, 2014
Cancer during pregnancy traditionally has been a rare phenomenon.Through the last third of the 20th century, about 1 in 1,000 pregnant women developed a malignancy…
CME
figure

Applying Imaging, Biomarkers, and Immunotherapy in the Management of NSCLC

This activity is supported by an educational grant from Genentech, Inc.

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, but the numerous subtypes make this disease…
More »
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »

Filter By:

figure In the Journals

Cetuximab plus radiation, cisplatin yielded little benefit in advanced head and neck cancers

September 12, 2014
The addition of cetuximab to cisplatin-based radiation therapy conferred no significant benefit with regard to PFS, OS, locoregional failure or…
figure Meeting News Coverage

Toxins at Ground Zero linked with cancer among thousands of first responders

September 11, 2014
The tragedy of Sept. 11, 2001 still haunts Americans in countless ways, with many survivors continuing to struggle with the enduring grief and trauma…
figure In the Journals

One in four patients with head, neck cancers do not receive guideline-directed adjuvant therapy

September 2, 2014
About 25% of patients with surgically resected head and neck cancers that exhibit adverse pathologic features do not receive guideline-directed…
figure Cover Story Publication Exclusive

Cancer treatment during pregnancy ‘a constant balancing act’

HemOnc Today, September 10, 2014
Cancer during pregnancy traditionally has been a rare phenomenon.Through the last third of the 20th century, about 1 in 1,000 pregnant women…
In the Journals

Surgery improved outcomes in advanced laryngeal cancer

August 26, 2014
Patients with advanced laryngeal cancer who underwent surgery experienced longer disease-specific survival and OS than those treated with nonsurgical…
In the Journals Perspective

Researchers identify risk factors for soft tissue necrosis in OSCC

August 19, 2014
A specific subset of patients with oropharyngeal squamous cell carcinoma who undergo transoral robotic surgery and postoperative radiotherapy…
Industry News

PDI, Inc. subsidiary acquires thyroid, cancer diagnostic tests

August 17, 2014
Continuing its path in commercializing molecular diagnostic tests, PDI, Inc. announced its Interpace Diagnostics subsidiary has acquired the…
figure In the Journals Perspective

Blood, saliva testing may predict recurrence of HPV-related head and neck cancers

August 13, 2014
Testing for HPV-16 DNA in saliva and plasma may be a useful predictor of recurrence in patients with oropharyngeal squamous cell carcinoma, according…
In the Journals

Co-existence of BRAF V600E, TERT promoter mutations predict recurrence in papillary thyroid cancer

August 1, 2014
Patients with papillary thyroid cancer who harbor BRAF V600E mutation and a specific telomerase reverse transcriptase promoter mutation are at…
Industry News

Thyroid association recognizes research grant collaboration of patient support groups

July 27, 2014
The American Thyroid Association has allied with Bite Me Cancer, a thyroid cancer patient support group, to deliver a newly awarded grant in…
More Headlines »